Syneos Health

Syneos Health, Inc. engages in the provision of outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded in 1998 and is headquartered in Morrisville, NC.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Syneos Health reports mixed Q4 results, focuses on growth strategies

Syneos Health's Q4 performance showed mixed results with revenue decline but growth on a constant currency basis. The company is focused on enhancing its operating model, customer engagement, and winning new business opportunities.
Challenges include evaluating spending by large pharma customers and the need for cost structure realignment. However, opportunities lie in engaging with analysts, driving cost savings, and expecting larger pharma awards in 2023.
Overall, Syneos Health remains confident in its strategy, investments, and ability to drive growth in Clinical. The company is navigating challenges while leveraging strengths in customer relationships and value-based pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

MORRISVILLE, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the promotions of two senior internal leaders – Baba Shetty to President, Technology and Data Solutions, and Suma Ramadas to Executive Vice President, Medical Affairs.

Syneos Health Promotes Baba Shetty to President, Technology and Data Solutions, and Suma Ramadas to Executive Vice President, Medical Affairs

MORRISVILLE, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, will release its first quarter 2022 financial results on Friday, April 29th, 2022, prior to its earnings call at 8:00 a.m. ET

Syneos Health Schedules First Quarter 2022 Earnings Call for Friday, April 29th, 2022

Let's see if Syneos Health, Inc. (SYNH) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Should Value Investors Pick Syneos Health (SYNH) Stock Now?

Syneos Health was formed in 2017 via a merger between 2 Contract Research Organizations, INC Research and inVentiv Health.

Syneos Health: Upside Opportunity After Unexpected Correction In CRO Market, M&A Rumors

Despite the near-term COVID-19 challenges, Syneos Health (SYNH) remains confident about the long-term strength of its business given the robust backlog and the unique market position.

Syneos Health (SYNH) Clinical Solutions Arm Grows Amid Cost Woe

Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental performance.

Here's Why You Should Retain Syneos Health (SYNH) For Now

Allscripts Healthcare Solutions

Medtronic

Stryker

MedTech stocks like Medtronic (MDT), Stryker (SYK), Allscripts Healthcare Solutions (MDRX) and Syneos Health (SYNH) are evolving rapidly in the field of AI-driven technologies.

4 Stocks in Spotlight With AI Making Inroads in MedTech

Syneos Health (SYNH) reports better-than-expected earnings for the fourth quarter and strong performances by the Clinical Solutions and Commercial Solutions arms.

Syneos Health (SYNH) Q4 Earnings Top Estimates, Margins Down

Syneos Health Inc. (SYNH) CEO Alistair Macdonald on Q4 2021 Results - Earnings Call Transcript

Syneos Health (SYNH) delivered earnings and revenue surprises of 3.50% and 2.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Q4 Earnings Beat Estimates

Syneos Health Reports Fourth Quarter and Full Year 2021 Results

MORRISVILLE, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, will release its fourth quarter and full year 2021 financial results on Thursday, February 17th, 2022, prior to its earnings call at 8:00 a.m. ET

Syneos Health Schedules Fourth Quarter and Full Year 2021 Earnings Call for Thursday, February 17th, 2022

Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada

MORRISVILLE, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has appointed two new independent directors, Barbara W. Bodem and Alfonso G. Zulueta, to its Board of Directors.

Syneos Health Appoints Two New Independent Directors

As Industry Dynamics Shift, Smaller Biotechnology Companies Will Continue to Drive Dealmaking in 2022 As Industry Dynamics Shift, Smaller Biotechnology Companies Will Continue to Drive Dealmaking in 2022

Syneos Health Releases 2022 Dealmakers' Intentions Survey

MORRISVILLE, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, today announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 10:30 a.m. EST.

Syneos Health to Present at the 40th Annual J.P. Morgan Healthcare Conference

Boston Scientific

DexCom

Stocks like Boston Scientific (BSX), Medtronic (MDT), DexCom (DXCM) and Syneos Health (SYNH) are evolving rapidly in the field of IoMT.

4 Internet of Medical Things (IoMT) Stocks to Buy for 2022

New Era of Biopharma Product Development to be Fueled by Value Creation, Human Centricity and Industry Change New Era of Biopharma Product Development to be Fueled by Value Creation, Human Centricity and Industry Change

Syneos Health Releases 2022 Health Trends

Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock?

Why Is Syneos Health (SYNH) Down 4.1% Since Last Earnings Report?

Syneos Health is delivering on its promises as the company reports strong revenue and free cash flow growth. The free cash flow is roughly twice as high compared to the net income due to lower capex requirements and high share-based compensation elements.

Syneos Health's Double-Digit Revenue Growth Sets The Tone For A Strong 2022

Investors about optimistic about Syneos Health (SYNH) given its better-than-expected results as well as strong segmental performance during the third quarter.

Here's Why You Should Hold on to Syneos Health (SYNH) for Now

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Syneos Health (SYNH) is a Top Momentum Stock for the Long-Term

Labcorp Holdings Inc

Laboratory Corp of America Holdings (NYSE: LH) is in talks to combine some of its assets with Syneos Health Inc (NASDAQ: SYNH), reports Bloomberg citing people with knowledge of the matter.  The companies are discussing a deal in which part of LabCorp's Covance clinical research division would merge with Syneos.

Labcorp In Talks To Merge Some Covance Assets With Syneos: Bloomberg

MORRISVILLE, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that the Company is scheduled to present at two upcoming investor conferences:

Syneos Health to Present at Upcoming Investor Conferences

Syneos Health (SYNH) reports better-than-expected results for third-quarter 2021 on strength in Clinical Solutions and Commercial Solutions arms driving the top line.

News for Syneos Health Stock (SYNH)